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Abstract Extracellular regulated kinases (ERKs) mediate the
inhibitory effect of tumor necrosis factor K (TNF-K) on
uncoupling protein-1 (UCP-1), but not on lipid accumulation.
TNF-K-induced ERK-dependent peroxisome proliferator activa-
tor receptor Q (PPARQ) phosphorylation could be responsible for
UCP-1 downregulation. Thus, the negative effect of TNF-K on
UCP-1 mRNA expression at 4^5 h, under basal conditions or in
cells treated with the PPARQ agonist, rosiglitazone, was reversed
by the MEK1 inhibitor PD98059. In contrast, fatty acid synthase
and malic enzyme mRNA downregulation was not prevented.
Moreover, rosiglitazone has no positive effect on adipogenic gene
expression or lipid accumulation. Therefore, there is a differ-
ential regulation of thermogenic and adipogenic differentiation
by PPARQ, which might account for the differences in the TNF-K
regulation through ERKs. 2 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Brown adipose tissue (BAT) is characterized by the pres-
ence of the uncoupling protein-1 (UCP-1) in mitochondria,
which allows the production of heat by ‘non-shivering ther-
mogenesis’ [1]. In rats, BAT development occurs at the end of
the fetal period and during the ¢rst days after birth [2].
Although some of the signals and mechanisms regulating
BAT development are known [3^6], there are many missing
links. In particular, the negative regulators of BAT are not
well characterized, although tumor necrosis factor K (TNF-K)
seems to play an important role [7,8]. TNF-K inhibits prolif-
eration [7,9], di¡erentiation [10] and induces apoptosis [7,9] in
rat fetal brown adipocytes, suggesting its importance in BAT
development regulation. In addition, based on experiments
performed in mice lacking TNF-K receptors [11], TNF-K ap-
pears to be responsible for BAT apoptosis, and the reduction
in UCP-1 expression observed in obese (ob/ob) mice.
We have found that TNF-K inhibits the expression of UCP-
1 and adipocyte-speci¢c genes in rat fetal brown adipocytes
[10]. Extracellular regulated kinase (ERK) activation by TNF-
K seems to mediate the decrease in UCP-1 expression, but not
that of adipogenic genes [10], although they are also negative
regulators of these genes [5,12]. Although CAAT enhancer
binding protein (C/EBP) K and L could be involved in the
inhibitory action of TNF-K, other transcription factors might
explain the di¡erent regulation of UCP-1 and adipogenic
genes by ERKs [10]. Here, we present evidence indicating
that the TNF-K-induced phosphorylation of peroxisome pro-
liferator activator receptor Q (PPARQ) via ERKs plays an
important role in the negative regulation of UCP-1. More-
over, PPARQ seems to have little relevance in adipogenesis
regulation in rat fetal brown adipocytes at this stage of di¡er-
entiation.
2. Materials and methods
2.1. Isolation of fetal brown adipocytes and culture
Brown adipocytes from 20-day-old rat fetuses were isolated [13] and
grown in minimum essential medium supplemented with 10% fetal
bovine serum for 24 h. The cells were then serum-starved overnight
and maintained in the presence or absence of TNF-K (10 ng/ml),
rosiglitazone (1 WM) or combinations of both for di¡erent time peri-
ods. To inhibit ERKs, cells were pretreated with the MEK1 inhibitor,
PD98059 (Calbiochem #513000) at 20 WM for 1 h.
2.2. Western blot analysis
UCP-1 and phospho-cAMP-regulatory element (CRE)-binding pro-
tein (CREB) were quanti¢ed in total cell extracts [9] by Western blot
analysis, using a UCP-1 polyclonal antibody generously given by Dr.
E. Rial and a phospho-CREB (ser 133) antibody from New England
Biolabs (#9191S).
Phosphorylated and unphosphorylated PPARQ were detected by
Western blot with a polyclonal antibody against PPARQ from Bio-
Mol (#SA-206) using nuclear extracts prepared as described [10].
2.3. Treatment with alkaline phosphatase
Nuclear extracts were incubated for 1 h at 4‡C with alkaline phos-
phatase (100 U/sample) from bovine intestinal mucosa a⁄nity puri¢ed
type VII-S (Sigma P 5521) previously bound to A⁄-Gel 10 active ester
agarose (Bio-Rad cat #153-6099).
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2.4. Flow cytometric analysis of lipid accumulation after staining with
Nile red
Lipid accumulation was measured in a FACScan £ow cytometer
(Becton-Dickinson) following lipid staining with Nile red (4 Wg/ml).
Total lipid content per cell and lipid content versus cell size were
quanti¢ed, determining the percentages of cells with di¡erent lipid
content.
2.5. RNA extraction and Northern blot analysis
Northern blot analysis and total RNA extraction was performed
[7]. Blots were hybridized with a UCP-1 [14], fatty acid synthase
(FAS) [15], malic enzyme [16] or c-jun probe [9] and with a 18S ribo-
somal probe to normalize.
2.6. Gel mobility shift assays
UCP-1 CRE mobility shift assays were performed as described [9],
using nuclear extracts. A speci¢c double-stranded oligonucleotide, 5P-
GGGAGTGACGCGCGTCTG-3P, which corresponds to positions
3139 to 3122 of the rat UCP-1 gene [17], was used.
2.7. Statistical analysis
Statistical analysis of the results was performed using paired Stu-
dent’s t-test.
3. Results and discussion
3.1. ERKs are responsible for the inhibitory e¡ect of TNF-K on
UCP-1 protein content but not on lipid accumulation in
brown adipocytes
TNF-K is a potent inhibitor of insulin-induced adipocytic
di¡erentiation in white and brown adipocytes [18] acting
through the impairment of insulin signaling [8,18] or by direct
inhibition of adipogenic gene expression [18]. In rat fetal
brown adipocytes, we also found a direct inhibitory e¡ect of
TNF-K on thermogenic and adipogenic di¡erentiation, where
ERKs are the mediators of the negative action of TNF-K on
UCP-1 mRNA, but not on FAS and malic enzyme mRNAs
[10]. Additional experiments to establish the relevance of this
pathway and the mechanisms involved have been done.
As shown in Fig. 1A, TNF-K diminished UCP-1 protein
content after 48 h of treatment, which was prevented by in-
hibition of ERKs with PD98059. UCP-1 level was slightly
increased by PD98059 under control conditions. In contrast,
the decrease in the lipid content induced by TNF-K after 48 h
(Fig. 1B) was not abolished by PD98059. Therefore, ERKs
mediate the inhibition of thermogenic but not adipogenic dif-
ferentiation induced by TNF-K.
Fig. 1. E¡ect of PD98059 on the inhibitory e¡ect of TNF-K on
UCP-1 protein content and lipid accumulation in brown adipocytes.
Serum-starved cells were triggered with TNF-K (10 ng/ml) for 48 h
and pretreated or not with 20 WM PD98059 for 1 h. A: Representa-
tive UCP-1 Western blot analysis and relative values from the densi-
tometric analysis expressed as fold increase, upper panel; Western
blot reblotted with anti-ERK1/2 to normalize, lower panel. Results
are means of three independent experiments, in which the variation
within the experimental group is less than 15%. B: Flow cytometric
analysis of total lipid content per cell after staining with Nile red.
Results are expressed as percentages compared with the control val-
ue, which is considered 100%, and are meansVS.E.M. of three inde-
pendent experiments. Statistical analysis was carried out by Stu-
dent’s t-test: ***P6 0.001 as compared with control.
Fig. 2. E¡ect of TNF-K on the binding activity to the AP-1/CRE
site in the UCP-1 promoter. Regulation by ERKs. Serum-starved
cells were triggered with TNF-K (10 ng/ml) for 30 min (A) or 2 h
(B, C) and pretreated or not with 20 WM PD98059 for 1 h. A:
Northern blot analysis of c-jun mRNA. A representative experiment
of three independent experiments is shown in the upper panel and
the c-jun/18S ratio in the lower panel. Results are meansVS.E.M.
of three independent experiments. Statistical analysis was carried
out by Student’s t-test: ***P6 0.001 as compared with control and
þþþP6 0.001 as compared with TNF-K-treated cells. B: Representa-
tive UCP-1-CRE gel shift assay, lower panel; relative values from
the densitometric analysis, upper panel. Results are means of three
independent experiments, in which the variation within the experi-
mental group is less than 15%. C: Representative phospho-CREB
Western blot.
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3.2. c-Jun is not responsible for the inhibition of the UCP-1
expression induced by TNF-K
The inhibitory action of TNF-K was partially correlated
with changes in C/EBPK and L proteins and in their DNA
binding activity, mediated through ERKs [10]. However, these
changes did not explain the di¡erent regulation exerted by
ERKs on UCP-1 and adipogenic genes expression. Thus, oth-
er transcription factors might be involved.
Searching for other transcription factors, we investigated c-
Jun, which can be upregulated through the ERK pathway
[19]. c-Jun can inhibit UCP-1 gene expression through binding
to the proximal CRE region of its promoter [17]. Hence, we
checked whether changes in c-Jun levels could regulate UCP-1
expression in TNF-K-treated cells. TNF-K increased c-jun
mRNA levels, whereas MEK inhibition by PD98059 abol-
ished this e¡ect (Fig. 2A). However, gel shift assays using
an UCP-1-CRE oligonucleotide did not reveal any signi¢cant
change in the DNA binding activity inducible by TNF-K,
either in the presence or absence of PD98059, at 2 h (Fig. 2B)
or at other time periods (not shown). As CREB/ATF family
members can also bind this site, leading to activation of the
UCP-1 promoter [17], we quanti¢ed phospho-CREB levels.
We found very high levels of phospho-CREB in control cells,
which remained constant from 5 min up to 48 h with di¡erent
treatments (Fig. 2C). Hence, it is very unlikely that c-Jun can
regulate UCP-1 through the CRE site. On the contrary, be-
cause of the high levels of CREB, this transcription factor
would preferentially bind to this site avoiding any possible
regulation by c-Jun.
3.3. ERKs mediate TNF-K-induced phosphorylation of PPARQ
PPARQ is another transcription factor that activates the
expression of certain adipogenic genes [20^22] and the UCP-
1 gene [21,23^25]. It can be regulated by ligand binding, phos-
phorylation, coactivators, transcriptional mechanisms and li-
gand-dependent proteolysis [10,22,25,26]. We analyzed the
possible role played by PPARQ on TNF-K e¡ects through
an ERK-dependent mechanism.
Fig. 3. E¡ect of TNF-K and the speci¢c PPARQ ligand, rosiglitazone, on UCP-1 and lipogenic gene mRNA expression and its regulation by
ERKs. Possible role played by TNF-K-induced PPARQ phosphorylation. Serum-starved cells were triggered with TNF-K (10 ng/ml) for 10^15
min (A) or 4^5 h (B) and/or with rosiglitazone (1 WM) for 4^5 h. When indicated, they were pretreated with 20 WM PD98059 for 1 h. A: Rep-
resentative PPARQ Western blots performed with nuclear extracts pretreated or not with alkaline phosphatase. B: Representative Northern blot
analysis of UCP-1, malic enzyme (ME) and FAS mRNAs and fold increase of these mRNAs normalized with 18S ribosomal probe. Values are
means of three independent experiments, in which the variation within the experimental group is less than 15%.
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In 3T3 L1 cells, TNF-K can decrease PPARQ mRNA and
protein levels depending on the dose and time of treatment
[27]. Therefore, we ¢rst examined the possible regulation of
PPARQ mRNA and protein levels by TNF-K through ERKs,
but no changes were found (not shown) upon TNF-K treat-
ment for 24 up to 48 h. Therefore, other mechanisms might be
operating, e.g. phosphorylation through ERKs.
PPARQ serine residues are phosphorylated by ERKs upon
insulin treatment in 3T3 L1 cells [28], but it has never been
shown that TNF-K can induce this phosphorylation. We in-
vestigated this possibility by looking for the retardation of the
PPARQ band in a Western blot, as is detected in insulin-in-
duced phosphorylation. We analyzed PPARQ in nuclear ex-
tracts from cells treated with TNF-K for 10^15 min (pre-
treated or not with PD98059). TNF-K induced a shift in the
PPARQ band that was abolished by pretreatment with
PD98059 (Fig. 3A). Treatment of nuclear proteins with alka-
line phosphatase also suppressed this shift, which indicates
that PPARQ band shift is due to its phosphorylation. There-
fore, these results indicate that TNF-K induces the phosphor-
ylation of PPARQ through ERKs.
3.4. Relevance of PPARQ in the inhibitory e¡ect of TNF-K on
thermogenesis, but not on adipogenesis
ERK-mediated phosphorylation of PPARQ upon insulin
treatment has been associated with the inhibition of adipogen-
ic di¡erentiation [28], but it is unknown whether it can play
any role in the inhibitory e¡ect of TNF-K on adipogenic and
thermogenic di¡erentiation in brown adipocytes. We explored
this by measuring the e¡ect of ERK inhibition on the TNF-K
actions, which regulate mRNA expression for UCP-1 and for
some adipogenic genes. We also studied whether TNF-K could
modulate the e¡ect of the selective PPARQ agonist, rosiglita-
zone, on the levels of these mRNAs, in either the absence or
presence of PD98059. Since PPARQ agonists are able to in-
duce the expression of the UCP-1 mRNA in brown adipocytes
at 4 h by a mechanism dependent on ligands but not protein
synthesis [29], all these studies were done with short incuba-
tions (1^5 h). In this way, it is very likely that we can detect
the e¡ect of PPARQ phosphorylation on the mRNAs expres-
sion.
We did not observe any change in the expression of UCP-1,
FAS and malic enzyme mRNAs before 4 h (data not shown).
However, at 4 h, UCP-1 mRNA expression was decreased by
TNF-K, and pretreatment with PD98059 abolished this e¡ect
(Fig. 3B, left panel). Rosiglitazone induced an increase in
UCP-1 mRNA level, that was enhanced by ERKs inhibition
and blocked by TNF-K. Pretreatment with PD98059 restored
the positive e¡ect of rosiglitazone (Fig. 3B, left panel). These
results were con¢rmed by studies carried out at 5 h (Fig. 3B,
right panel), with the only di¡erence that the positive e¡ect of
rosiglitazone was much higher at this time and, consequently,
it was not totally inhibited by TNF-K.
In contrast, FAS and malic enzyme mRNAs levels were
decreased by TNF-K at 4 and 5 h (Fig. 3B), but this e¡ect
was not prevented by PD98059, although a partial reversion
was observed in the case of the malic enzyme mRNAs. Sur-
prisingly, rosiglitazone did not increase FAS and malic en-
zyme mRNAs expression, in either the presence or absence
of PD98059. Moreover, rosiglitazone induced a signi¢cant
decrease of FAS mRNA at 5 h either alone or in combination
with TNF-K or TNF-K plus PD98059. Therefore, there does
not seem to be a clear regulation of adipogenesis by PPARQ
and/or its phosphorylation at the level of these lipogenic
genes. However, based on the fact that there are no clear
peroxisome proliferator activator response element (PPRE)
sites in the FAS promoter [30] and those PPRE sites in the
malic enzyme promoter are more likely to be activated by
PPARK [31], it would be possible that PPARQ-dependent ac-
tivation of adipogenesis could be exerted by modulation of
other adipogenic-related genes [20,30]. We quanti¢ed possible
changes in lipid accumulation. As shown in Fig. 4A, treat-
ment with TNF-K for 64 h decreased cellular lipid content and
inhibition of ERKs did not prevent it. Moreover, treatment
with rosiglitazone had no signi¢cant e¡ect on lipid content
and the presence of PD98059 induced a decrease. Therefore,
these results con¢rmed data from FAS and malic enzyme
mRNA analysis.
It has been described that some of the actions of rosiglita-
Fig. 4. E¡ect of TNF-K and the speci¢c PPARQ ligand, rosiglita-
zone, on lipid accumulation and its regulation by ERKs. Flow cyto-
metric analysis of cellular lipid content after staining with Nile red.
Serum-starved cells were triggered with TNF-K (10 ng/ml) and/or
with rosiglitazone (1 WM) for 64 h and pretreated or not with 20
WM PD98059 for 1 h. A: Total lipid content per cell. B: Percentage
of large cells with high lipid content (28% in controls). A and B:
Results are expressed as percentages compared with the control val-
ue, which is considered 100%, and are meansVS.E.M. of four inde-
pendent experiments. Statistical analysis was carried out by Stu-
dent’s t-test: ***P6 0.001; **P6 0.01 as compared with control;
þþP6 0.01 as compared with rosiglitazone treatment.
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zone and other thiazolidinediones in white adipocytes are due
to the induction of an increase in the number of small white
adipocytes, while decreasing the number of large white adipo-
cytes [21]. Based on this, we analyzed changes in the lipid
content in the di¡erent subpopulations of brown adipocytes
by £ow cytometry. We detected a signi¢cant increase in the
percentage of large cells with a high lipid content (Fig. 4B),
that was abolished by PD98059 pretreatment.
In conclusion, our present results indicate that PPARQ is
important for the thermogenic di¡erentiation of rat fetal
brown adipocytes, but seems to have little relevance for adipo-
genesis at this stage of di¡erentiation, regulating only the mat-
uration of a small subpopulation of cells (large cells with high
lipid content). This would explain the di¡erences in the TNF-
K regulation of thermogenic and adipogenic di¡erentiation
through ERKs. The relevance of PPARQ in the regulation
of UCP-1 expression agrees with previous results obtained
in cells maintained in culture [23,24,32,33] and with the ab-
sence of BAT in PPARQ knock-out mice after the rescue of
the placenta defects [21].
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